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For the release of pharmaceutical products into the drug market; most of the pharmaceutical companies 
depend on acceptance criteria - that are set internally, regulatory and/or pharmacopeially. However, 
statistical process control monitoring is underestimated in most quality control in cases; although it 
is important not only for process stability and efficiency assessment but also for compliance with all 
appropriate pharmaceutical practices such as good manufacturing practice and good laboratory practice, 
known collectively as GXP. The current work aims to investigate two tablet inspection characteristics 
monitored during in-process control viz. tablet average weight and hardness. Both properties were assessed 
during the compression phase of the tablet and before the coating stage. Data gathering was performed 
by the Quality Assurance Team and processed by Commercial Statistical Software packages. Screening 
of collected results of 31 batches of an antibacterial tablet - based on Fluoroquinolone -showed that all 
the tested lots met the release specifications, although the process mean has been unstable which could 
be strongly evident in the variable control chart. Accordingly, the two inspected processes were not in 
the state of control and require strong actions to correct for the non-compliance to GXP. What is not 
controlled cannot be predicted in the future and thus the capability analysis would be of no value except 
to show the process capability retrospectively only. Setting the rules for the application of Statistical 
Process Control (SPC) should be mandated by Regulatory Agencies.
Keywords: Statistical process control (SPC). In-process control. GXP. Film coated tablet. Fluoroquinolone. 
Capability analysis. Pharmaceutical practice.
INTRODUCTION
The core value around which pharmaceutical 
industry is basically centered is the delivery of medicinal 
products which fulfill five criteria namely: Safety - 
Identity -Strength - Purity - and Quality (SISPQ) (Welty, 
2009). The deficiencies in products quality delivered to 
final customer may not be obvious to the consumer, so 
the Quality Team is a crucial defense line that protects 
both patients and manufacturers from consequences 
of delivering non-conforming drug products to the 
market. However, the problem exacerbation may be due 
to its effect(s) on employees’ morals and attitudes due 
to deficiency in quality. Thus, if the quality concept is 
not communicated efficiently within the organization, 
the consequences on the impacted products would be 
devastating (Asotra, Cossin, Yacobi, 2012). 
For any firm to work with high‑quality standards 
level, an efficient Quality Control (QC) system must be 
implemented (Spiridonică, 2011). Since achieving highest 
levels of quality standards are hindered by the extent of 
variability, thus, the main value of Statistical Process 
Control (SPC) resides in reducing the variability in the 
manufacturing process (Spiridonică, 2011). The concept 
of the continuous improvement in any organization by 
reducing variability is critical for both SPC and overall 
Quality Management (Ciobanu, Schreiner, 2002).
Due to above-mentioned challenges, present 
work aims to investigate the current state of control 
for a pharmaceutical product manufactured in a new 
pharmaceutical firm. Furthermore, monitoring the 
process stability would provide assurance on future 
process yield consistency. The study also focused on 
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detecting the compliance of manufactured product to best 
pharmaceutical practice which may be referred to, here, 
as GXP through SPC. The study scope will cover two 
inspection properties of a pharmaceutical product viz. the 
average weight and hardness of tablet. By using SPC, the 
current state of manufacturing control can be evaluated 
for monitoring of both characteristics. Moreover, the 
current state of the process stability would determine the 
consistency and steadiness of inspected characteristic. 
This is considered a crucial integral part of product 
manufacturing good practices. Accordingly, the product 
value could be evaluated through the degree of compliance 
with GXP.
MATERIAL AND METHODS
A non-sterile manufacturing pharmaceutical plant 
was established in the Industrial Zone at South Delta 
region in Egypt. The plant has begun launching products 
of class D production area for solid dosage forms (Eissa, 
2016a). During 2016, 31 batches of film coated tablets 
based on Fluoroquinolone - as an active pharmaceutical 
ingredient (API) - were manufactured, tested and released 
according to the specifications in Ministry of Health 
(MoH) product registration.
The current study is part of a large project covering 
different inspection characteristics of a variety of the 
firm’s medicinal dosage forms. The product is a film 
coated tablet that is composed of Levofloxacin (API: 
Broad spectrum antibiotic of Fluoroquinolone class 
(Briggs, Freeman, Yaffe, 2012; levoflaxin, 2017), hydroxy 
propyl methyl cellulose (Disintegrant), crospovidone 
(Disintegrant), Avicel PH 102 (Filler), sodium stearyl 
fumarate (Lubricant) and coating material (Coating film) 
(Eissa, Mahmoud, 2015; Sodium Stearyl Fumarate, 2017).
The manufacturing process includes the following 
steps: dispensing and weighing components from 
warehouse, blending, compaction followed by last 
blending step then compression, coating, blistering and 
packaging finally in secondary package to be transferred 
to the finished products warehouse. A process that is very 
common in solid oral dosage forms manufacturing and 
similar aspects have been discussed before by some field 
experts (Harbir, 2012; Mulla, 2015).
Two inspection characteristics were assessed in 
the production process during tablet core compression 
phase, namely: average weight and hardness. Results 
were collected from In-Process Control (IPC) monitoring 
logs and arranged batch‑wise in Microsoft Office Excel 
2007. Data were subjected to statistical analysis using 
GraphPad Prism Version 6.01 software for Windows. The 
analysis was performed as described in software manual 
guide (GraphPad Prism User Guide, 2015). Distribution 
identification and analysis was conducted using XLSTAT 
Version 2014.5.03 (Eissa, 2016b).Box-and-Whisker 
Plots and control charts were constructed using Minitab® 
Version 17.1.0 (Minitab 17, 2013).
RESULTS AND DISCUSSION
SPC tools and techniques have become an essential 
part of quality monitoring and improvement system 
in many industries including the pharmaceutical 
manufacturing field. The first step involved an overview 
on results, its pattern and data homogeneity. Analysis 
of results during data mining showed that the average 
tablet weight in the 20th batch was exceedingly high 
outlier (although not Out‑Of‑Specification (OOS)) value 
“692.13 mg” by Robust regression and Outlier removal 
method (ROUT) (Q = 1.0%) test during trending average 
weight results(GraphPad Prism User Guide, 2015). This 
unexpected result highlighted the need to further analyze 
to elucidate reason for such observation. On the other 
hand, hardness test results did not show any outliers 
preliminarily using GraphPad Prism. On the same line, 
Box-and-Whisker diagrams illustrated in Figure 1 
confirmed the absence of outliers (indicated by absence 
of asterisks “*”). Moreover, they showed the pattern of 
data distribution with a little degree of skewness towards 
the lower side (Lane, 2017). Minimum, 25% percentile, 
median, 75% percentile and maximum values for average 
weight and hardness were 644, 654, 660, 665, 669 and 15, 
16, 16, 17, 18.
The second step focused on the determination of 
the data distribution and degree of normality which was 
important in the interpretation of the trending charts in the 
study. Removal of abnormally high result from average 
weight data has improved normality by Anderson-Darling 
(AD) test from P =0.023 to P =0.110 (Support.minitab.
com, 2016). Interestingly, distribution fitting test showed 
that Weibull (2) distribution is the closest with P =0.982 
(The Weibull Distribution, 2017). In contrast, hardness 
data still demonstrated that normal distribution is the 
closest fit with P =0.9692. The Mean Value ± Standard 
Deviation (SD), skewness and kurtosis of average weight 
and hardness were 659±6.2 mg, 16±0.82 Kilopond (Kp), 
‑0.65, ‑0.20 and ‑0.31, ‑0.88, respectively. The coefficient 
of variation and the geometric mean were 0.94%, 659 
and 5.11%, 16, respectively. Figure 2 and 3 demonstrated 
normality of both average weight and hardness visually, 
respectively, using normal probability plot (The Anderson-
Darling Statistic, 2017). Thirdly, capability histogram was 
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interpreted for both of the inspection properties in order 
to determine the location of normally distributed process 
between specification limits (SLs). In addition, histograms 
were not centered within SLs and data was found to be 
shifted towards the lower average weight limit. While 
results of hardness strongly shifted towards the upper limit 
(Minitab 17, 2013).
Examination of the constructed process behavior 
(control) chart was inspected - after histograms 
examination to monitor the process. Shewhart charts were 
constructed for different types of data with a certain degree 
of normality using Individual-Moving Range (I-MR) chart 
as demonstrated in Figure 2 and 3. Normality assumption 
was confirmed to avoid errors in alarm detection while 
constructing Shewhart charts. I-MR is actually composed 
of two charts: I chart that determined the process state of 
control mean and MR chart which showed the process 
variation stability. Surprisingly, none of the inspected 
parameters showed acceptable stability, consistency or 
efficiency in the process (Smartersolutions.com, 2017). 
Interestingly, although the process variation (from MR 
charts) was stable (except for one point in hardness), the 
process center (I charts) was in “Out-of-Control” state 
especially in average weight. The assignable causes of 
fluctuations (indicated by batches represented in red 
dots) should be isolated from normal processes with 
common cause variations (Martz, 2013). Moreover, both 
processes are not centered and showed drifts toward either 
of the border specification limits with possible future 
excursions. This case was especially evident with hardness 
in capability analysis. Accordingly, capability plots have 
no value and may indicate past performance only but 
cannot provide future prediction unless the processes 
instability factors were corrected by Corrective Action 
and Preventive Action (CAPA) (Qimacros.com, 2017). 
Since there was no subgroups for each point, the last 25 
observations in Figure 2 and 3 are the same as in the last 
ones in I charts. Further investigation is required to figure 
out and correct the source of non-GXP activities which 
might stem from the manufacturing and/or IPC activities.
The current study demonstrated the need to establish 
an official requirement for SPC in pharmaceutical 
monitoring as a part of routine quality system through 
Regulatory bodies to solve the non-compliant activities 
concurrently and immediately rather than retrospectively. 
SPC provides strong control and verification of newly 
established operation efficiency and the needed 
adjustments if the process is not working satisfactorily. 
To conclude, the pharmaceutical dosage forms may meet 
the specification limits required for the product release, 
while hiding signs of future excursions that may turn into 
true OOS. Moreover, SPC provides visual evidence of 
process stability accompanied with GXP.
Accordingly, it could be concluded from previous 
study that the inspection characteristics monitoring of 
pharmaceutical products should take into consideration 
each of the following:
1. SPC could provide a visual measure of specific 
procedure compliance with GXP.
2. The importance of official regulatory enforcements 
for implementation of SPC within pharmaceutical 
industry especially in developing countries.
3. Monitoring overall manufacturing cycle perfor-
mance of product rather than reliance on product re-
lease specifications only may show the gap between 
delivered into market product, its true manufacturing 
quality conditions and the environment within which 
it has been manufactured.
FIGURE 1 - Box Plot diagram showing the pattern of data 
distribution for average weight and hardness as part of IPC tests 
during the compression process.
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FIGURE 2 - Statistical control monitoring of average weight test showing out-of-control points as red dots.
FIGURE 3 - Statistical control monitoring of hardness test showing out-of-control points as red dots.
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4. The application of the current method is simple and 
saves time using a statistical software package, yet 
its full potential in product quality process monitor-
ing is crucial.
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